Savicell jobs and careers
Israel
As of October 23, 2026, Savicell has no open roles listed.
About Savicell
THE IMMUNOBIOPSY™ COMPANY – BECAUSE EARLY DETECTION IS LIFE™ The Savicell™ Well-Shield™ platform is a blood test inherently designed for the early detection of disease. Cancer is our first focus. Savicell™ has a first-in-class liquid ImmunoBiopsy™ platform designed for the early detection of disease. The platform identifies multiple diseases and may be used to track treatment effectiveness, including immunotherapy. The Company’s initial focus is on the multi-billion dollar, underserved cancer liquid biopsy market. Metabolic changes in the immune system modulate cell fate and function, influencing immune response outcomes. These energy changes give the immune system the ability (effector function) to attack disease, including cancer. Diseases produce unique signatures in immune metabolic profiles that ImmunoBiopsy™ uses to distinguish between and within various ailments, such as cancers, autoimmune diseases, and infectious diseases. Savicell’s Liquid ImmunoBiopsy measures the energy changes of the immune system, which are disease-specific, and identifies the ailment.
- Founded
- 2007
- Employees
- 1 to 10
- Headquarters
- Israel
Leadership
The top of Savicell's org chart, with how many people report into each leader.
Ian Welsford
EVP QA/RA
Jobs at Savicell
No open positions right now. Explore more companies on TheJobsMap.
Savicell jobs: common questions
- Is Savicell hiring right now?
- Savicell has no open roles listed as of October 23, 2026. Roles appear here as soon as they are posted on Savicell's careers site.
- Where is Savicell headquartered?
- Savicell is headquartered in Israel and was founded in 2007.
- Who leads Savicell?
- Ian Welsford, EVP QA/RA, is at the top of Savicell's org chart.
- How do I apply for a job at Savicell?
- Pick a role on Savicell's TheJobsMap page and select Apply. Every listing links to the original posting on Savicell's own careers site, so you apply directly with the employer.